New Insights into the Use of Cytotoxic Agents for Cancer Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 8283
Special Issue Editor
Interests: metronomic chemotherapy; geriatric oncology; combined treatment modalities; novel therapeutic targets; breast cancer; ovarian cancer; prostate cancer; RCC; urothelial cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Chemotherapy has been used for more than 70 years for the treatment of cancer. However, its modern use in clinical practice is very different to its use even 20 years ago. With the use of antibody–drug conjugates, chemo-immunotherapy, and chemoradiotherapy, a totally new era of cancer treatment has recently begun. This Special Issue is aimed at collecting and summarizing the recent advances in novel applications of chemotherapy in clinical practice and in clinical trials.
I welcome submissions regarding:
- Novel antibody–drug conjugates
- The use of antibody–drug conjugates in:
- Breast cancer
- Urothelial cancer
- Chemoimmunotherapy in:
- Breast cancer
- Lung cancer
- Head and neck cancer
- Gastric cancer
- Novel cytotoxic agents
- Novel strategies of treatment with cytotoxic agents as metronomic chemotherapy
- Breast cancer
- Ovarian cancer
- Gastrointestinal cancers
- Brain tumors
- Novel predictive factors for chemotherapy
I look forward to receiving your contributions.
Dr. Piotr J. Wysocki
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antibody-drug conjugates
- metronomic chemotherapy
- chemoimmunotherapy
- sacituzumab govitecan
- trastuzumab emtansine
- trastuzumab deruxtecan
- enfortumab vedotin
- solid tumors
- breast cancer
- ovarian cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.